Roche targets 2021 start for hemophilia A gene therapy phase 3 as optimization effort drags on

Roche targets 2021 start for hemophilia A gene therapy phase 3 as optimization effort drags on

Source: 
Fierce Biotech
snippet: 

Roche has posted updated clinical data on a hemophilia A gene therapy it acquired in its $4.3 billion takeover of Spark Therapeutics. The study linked SPK-8011 to improvements in factor VIII expression and bleeding out as far as 3.3 years after administering the therapy, but, with Spark still optimizing the regimen, it will be 2021 before phase 3 dosing begins.